US Stock MarketDetailed Quotes

AKLI Akili

Watchlist
  • 0.288
  • -0.002-0.72%
Trading Mar 28 14:38 ET
22.63MMarket Cap-378P/E (TTM)

About Akili Company

Akili, Inc.(formerly Social Capital Suvretta Holdings Corp. I) , a commercialized company that develops digital therapies that combine science and technology to address cognitive disorders such as patient inattention, memory loss, difficulty learning new skills, and difficulty making decisions, is a new category of software-based medicine. The company has used its approach to technology that targets the brain directly to build a new class of drugs - drugs that have been validated in clinical trials, such as drugs or medical devices. The company's platform is powered by a proprietary therapeutic engine designed to target cognitive disorders in the brain, informed by decades of research and validated by a rigorous clinical program.

Company Profile

SymbolAKLI
Company NameAkili
Listing Date06/30/2021
Founded2020
CEOMr. Matthew Franklin
MarketNASDAQ
Employees68
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address71 Commercial Street
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02109
Phone1-617-313-8853

Company Executives

  • Name
  • Position
  • Salary
  • Matthew Franklin
  • Director, President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
  • 1.38M
  • Jacqueline L. Studer
  • Chief Legal Officer and Secretary
  • 873.07K
  • Dr. W. Edward Martucci, II,PhD
  • Chairman of the Board
  • 1.29M
  • Dr. Adam Gazzaley, M.D.,PhD
  • Director and Chief Science Advisor
  • 126.45K
  • William B.J. Jones, Jr
  • Independent Director
  • 77.88K
  • Mary Hentges
  • Independent Director
  • 86.75K
  • Christine Lemke
  • Independent Director
  • 74.25K
  • John Spinale
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg